Product Description
Mechanisms of Action: Camptothecin Analogue,TOP Stabilizer
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Peritoneal Cancer|Ovarian Cancer|Small Cell Lung Cancer|Fallopian Tube Cancer|Squamous Cell Carcinoma|Head and Neck Cancer
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
I138 | P2 |
Completed |
Peritoneal Cancer|Fallopian Tube Cancer|Ovarian Cancer |
2002-10-22 |
|
EORTC-16008 | P2 |
Completed |
Squamous Cell Carcinoma|Head and Neck Cancer |
2002-08-01 |
|
I123 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2001-06-08 |
|
NCT00046787 | P2 |
Completed |
Small Cell Lung Cancer |
None |